@prefix bqmodel: <http://biomodels.net/model-qualifiers/> .
@prefix dc: <http://purl.org/dc/elements/1.1/> .
@prefix prism: <http://prismstandard.org/namespaces/basic/2.0/> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .

<http://omex-library.org/BIOMD0000000913.omex> bqmodel:isDescribedBy <local:00001> ;
    prism:keyword "Biomodels" ;
    dc:description """<body xmlns="http://www.w3.org/1999/xhtml">
  <p>&lt;notes xmlns=&quot;http://www.sbml.org/sbml/level2/version4&quot;&gt;
      &lt;body xmlns=&quot;http://www.w3.org/1999/xhtml&quot;&gt;
        &lt;pre&gt;Optimal control of mixed immunotherapy and chemotherapy of tumors

Lisette Depillis, K. R. Fister , W. Gu, Tiffany Head, Kenny Maples, Todd Neal, Anand Murugan and Kenji Kozai
Abstract

We investigate a mathematical population model of tumor-immune interactions. Thepopulations involved are tumor cells, specific and non-specific immune cells, and con-centrations of therapeutic treatments. We establish the existence of an optimal con-trol for this model and provide necessary conditions for the optimal control triple forsimultaneous application of chemotherapy, tumor infiltrating lymphocyte (TIL) ther-apy, and interleukin-2 (IL-2) treatment. We discuss numerical results for the combina-tion of the chemo-immunotherapy regimens. We find that the qualitative nature of ourresults indicates that chemotherapy is the dominant intervention with TIL interactingin a complementary fashion with the chemotherapy. However, within the optimal con-trol context, the interleukin-2 treatment does not become activated for the estimatedparameter ranges.</p>
</body>""" ;
    dc:title "OPTIMAL CONTROL OF MIXED IMMUNOTHERAPY AND CHEMOTHERAPY OF TUMORS" .

<local:00001> rdfs:label "L. G. DE PILLIS, K. R. FISTER, W. GU, TIFFANY HEAD, KENNY MAPLES, TODD NEAL, ANAND MURUGAN & KENJI KOZAI. OPTIMAL CONTROL OF MIXED IMMUNOTHERAPY AND CHEMOTHERAPY OF TUMORS. Journal of Biological Systems 16, 01 (2008)." ;
    dc:identifier <http://identifiers.org/doi/10.1142/S0218339008002435> .

